N/A N=57 Effect of Diabetes Mellitus on Cholesterol Metabolism
Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus · Hypercholesterolemia
Primary: Changes in LDL Cholesterol — -0.83; -1.47; -0.93; -0.32 mmol/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=93 Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)
Hypercholesterolemia · Diabetes Mellitus, Type 2 · Coronary Disease
Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint, After 6 Weeks of Treatment — -32.2; -20.8 percentage change — p=0.005
Phase 4 N=14 Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Mean ApoB Concentration Before and After Evolocumab — 75.9; 35.3 mg/dL — p=<0.001
Phase 4 N=151 CHOlesterol Lowering and Residual Risk in Type 2 Diabetes
Type 2 Diabetes
Primary: Percent Change in Platelet Activity (MPA) Before and After Cholesterol Reduction — -5; -7 percent change in platelet aggregation
N/A N=1,049 LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts
Hypercholesterolemia With Concomitant Type 2 Diabetes
Primary: Percent Change in Non-high-density Lipoprotein Cholesterol (HDL-C) Level — -31.3; -32.8 Percent change
Phase 3 N=418 Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia
Type II Diabetes Mellitus · Dyslipidemia
Primary: Percent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C) — -40.78; -43.25 percent change
Phase 4 N=413 Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
Dyslipidemia
Primary: Percent Change From Baseline in Non-HDL-C at Week 24: Overall Intent-to-treat (ITT) Analysis — -37.3; -4.7 Percent change — p=<0.0001
Phase 3 N=424 Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
Hypercholesterolemia · Mixed Dyslipidemia · Type 2 Diabetes
Primary: Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 — -0.84; -64.98 percent change — p=<0.0001
Phase 2 N=242 Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C
Diabetes · Diabetes Mellitus, Type 2 · Cholesterolemia
Primary: Percent Change From Baseline to Week 12/End of Study (EOS) in Low-density Lipoprotein Cholesterol (LDL-C) — -38.8; -19.2; 0.9 Percent change — p=<0.001
N/A N=111 Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes
Type 2 Diabetes · African American · Cholesterol
Primary: ApoB Levels in African American Men With Diabetes and Those Without. — 80; 65 mg/dL — p==0.002
Phase 3 N=986 Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia
Diabetes, Hyperlipidemia, Mixed Dyslipidemia
Primary: Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 — 4.94; 0.99; -65.35; -69.05 percent change — p=<0.0001
Phase 4 N=152 A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)
Hypercholesterolemia
Primary: Change in Glycated Hemoglobin (HbA1c) From Baseline — 0.22; 0.14 Percent
Phase 3 N=517 Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Hypercholesterolaemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis — -51.8; -3.9; -48.2; 0.8 percent change — p=<0.0001
Phase 3 N=1,143 Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)
Hypercholesterolemia · Metabolic Syndrome
Primary: Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6 — -36.5; -49.6; -39.4; -53.9 Percent Change — p=<0.001
Phase 4 N=57 Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females
Atherogenic Dyslipidemia · Obesity Associated Disorder
Primary: Changes Serum Triglyceride Levels — 223.1; 241.2; 227.0; 267.2 mg/dl — p=0.0001
Phase 4 N=161 Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia
Hypercholesterolemia With Type2DM
Primary: Proportion of Patients Achieving LDL- C<100mg/dL — 61; 54 Participants
Phase 3 N=20 Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study
Metabolic Syndrome X
Primary: Change in Intestinal mRNA Expression Levels of LDL Receptor Between the Two 12-week Interventions — 110531; 95140 #copies/100000 copies housekeeping gene
Phase 3 N=1,547 MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)
Hypercholesterolemia
Primary: Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I) — -24.8; -10.1; -13.8 Percentage Change — p=<0.001
Phase 3 N=1,053 Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)
Hypercholesterolemia
Primary: Percent Change From Baseline in LDL-C at Week 6 — -26.7; -12.8 Percent Change — p=<0.001
Phase 4 N=75 Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling
Hyperlipidemia · Insulin Resistance · Type 2 Diabetes
Primary: Steady-state Plasma Glucose (SSPG) — 130; 139 mg/dL — p=0.01
N/A N=78 Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM
Diabetes Mellitus, Type II
Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change
Phase 1 N=107 Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
Diabetes Melliuts, Type 2
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 11; 15; 10; 13 participants
Phase 3 N=53 A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs
Pre-diabetes
Primary: Change in High-sensitivity C-reactive Protein — 0.72; -0.61 mg/dl
Phase 4 N=12 Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)
Diabetes Mellitus, Type 2 · Hypercholesterolemia
Primary: Change in Plasma LDL Cholesterol — -0.1 mmol/L
Phase 3 N=808 Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)
Cardiovascular Disorder · Diabetes Mellitus
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin…
Phase 3 N=796 Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)
Diabetes Mellitus Type 2
Primary: Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo — -15.8; 2.1…
Phase 2 N=9 Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes
Type 1 Diabetes Mellitus · Dyslipidemia
Primary: Change in LDL-c From Baseline to 6 Months in Subjects With Type 1 Diabetes Taking Vytorin or Zocor. — -67; -6 mg/dl
Phase 3 N=36 Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes
Diabetes Mellitus · Postprandial Lipemia
Primary: Measurement of the Area Under the Curve of Plasma Triglycerides (TG) Levels During Postprandial Period (Time 0,2,4,6,8 Hours) — 30.0; 27.1 mmol*h/L
Phase 3 N=129 Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia
Hypercholesterolemia · Dyslipidemia
Primary: Reduction of LDL Cholesterol Levels — -39.45; -29.13 percent change of LDL — p=0.0013
Phase 4 N=25 Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons
Coronary Heart Disease
Primary: Cholesteryl Ester Fractional Clearance Rate